RNA sequencing (RNAseq) can reveal gene fusions, splicing variants, mutations/indels in
addition to differential gene expression, thus providing a more complete genetic picture than …

The most common type of lung cancer is adenocarcinoma (ADC), comprising around 40% of
all lung cancer cases. In spite of achievements in understanding the pathogenesis of this …

The combination of next-generation sequencing and advanced computational data analysis
approaches has revolutionized our understanding of the genomic underpinnings of cancer …

The use of tyrosine kinase inhibitors (TKI) with activity against ALK, ROS1, or TRKA–C can
result in significant clinical benefit in patients with diverse tumors harboring ALK, ROS1, or …

Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was
evaluated in two phase I studies in patients with advanced or metastatic solid tumors …

Background Recurrent gene fusions, such as ROS1 fusions, are oncogenic drivers of
various cancers, including non-small-cell lung cancer (NSCLC). Up to 36% of patients with …

Non-small-cell lung cancers (NSCLCs), the most common lung cancers, are known to have
diverse pathological features. During the past decade, in-depth analyses of lung cancer …

The gene encoding the receptor-tyrosine kinase RET was first discovered more than three
decades ago, and activating RET rearrangements and mutations have since been identified …

Structural chromosome rearrangements may result in the exchange of coding or regulatory
DNA sequences between genes. Many such gene fusions are strong driver mutations in …

Structural gene rearrangements resulting in gene fusions are frequent events in solid
tumours. The identification of certain activating fusions can aid in the diagnosis and effective …